Skip to main content
    C

    Century Therapeutics Inc (IPSC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.64
    -0.01 (-0.61%)

    Market Cap: $299.63M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Century Therapeutics Inc (IPSC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Century Therapeutics reported revenue of $109.16M for the fiscal year ended Dec 31, 2025, up 1556.8% from the year before. That year, net income was -$9.58M with a net margin of -8.8%, operating cash flow was -$103.88M and free cash flow was -$104.72M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$23.45M.

    Revenue and Margins

    The operating margin was -15.8% in the fiscal year ended Dec 2025. Over the 10 years to Dec 2025, revenue fell from $950.79M, a compound annual decline of 19.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$109.16M+1556.8%100.0%-15.8%-8.8%
    Dec 2024$6.59M+194.8%100.0%-2096.5%-1920.9%
    Dec 2023$2.23M-57.0%100.0%-6556.9%-6115.1%
    Dec 2022$5.20MN/A100.0%-2574.2%-2518.4%
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2016$470.32M-50.5%0.5%N/AN/A
    Dec 2015$950.79MN/A6.5%N/AN/A
    Annual, fiscal years ended Dec 2015 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2016Dec 2015
    Revenue$109.16M$6.59M$2.23M$5.20M$0$0$0$470.32M$950.79M
    Cost of revenue$0$0$0$0$0$0$249.00K$467.84M$888.81M
    Gross profit$109.16M$6.59M$2.23M$5.20M$0$0-$249.00K$2.48M$61.97M
    Research and development$95.67M$107.24M$97.71M$107.17M$75.65M$44.40M$14.27M$9.09M$11.44M
    Operating income-$17.27M-$138.14M-$146.55M-$133.83M-$94.88M-$53.90M-$20.03MN/AN/A
    Net income-$9.58M-$126.57M-$136.67M-$130.93M-$95.82M-$53.58M-$244.77MN/AN/A
    EBITDA-$6.25M-$129.29M-$137.78M-$122.10M-$92.63M-$51.76MN/AN/AN/A
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$109.16M$4.17M$791.00K$771.00K$855.00K$268.00K
    Gross profit$0$0$0-$3.55M$0$0$109.16M$4.17M$791.00K$771.00K$855.00K$268.00K
    Operating income-$25.21M-$36.53M-$23.68M-$20.66M-$36.12M-$34.66M$74.18M-$37.28M-$34.79M-$34.76M-$31.31M-$43.76M
    Net income-$23.45M-$34.55M-$21.64M-$19.18M-$34.42M-$32.54M$76.56M-$36.07M-$31.23M-$31.21M-$28.06M-$39.40M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $3.76M by $58.10M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2016Dec 2015
    Total assets$223.70M$353.22M$360.69M$486.54M$437.38M$106.78M$90.90M$758.00M$844.70M
    Current assets$120.77M$194.05M$176.99M$319.72M$228.15M$78.80M$84.12MN/AN/A
    Cash and equivalents$61.85M$58.44M$47.32M$84.27M$56.45M$27.21M$44.06M$21.47M$208.00K
    Total liabilities$64.77M$191.85M$175.94M$183.81M$41.14M$33.43M$182.75M$575.54M$484.99M
    Short-term debt$3.76M$0$1.51M$6.50M$1.04M$0N/AN/AN/A
    Long-term debtN/AN/AN/A$3.74M$8.90M$9.64MN/A$275.38M$156.34M
    Shareholder equity$158.94M$161.36M$184.75M$302.74M$396.24M-$106.41M-$91.86M$182.46M$359.71M
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$262.63M$287.01M$326.55M$223.70M$244.72M$284.69M$315.61M$353.22M$388.62M$416.45M$348.51M$360.69M
    Total liabilities$52.66M$54.66M$61.81M$64.77M$68.37M$74.79M$75.17M$191.85M$192.93M$194.34M$170.62M$175.94M
    Cash and equivalents$45.02M$49.64M$51.05M$61.85M$55.52M$56.88M$51.87M$58.44M$52.59M$41.46M$46.81M$47.32M
    Shareholder equity$209.97M$232.34M$264.74M$158.94M$176.35M$209.90M$240.44M$161.36M$195.69M$222.10M$177.88M$184.75M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2016Dec 2015
    Operating cash flow-$103.88M-$110.14M-$88.35M$14.05M-$89.00M-$41.27M-$16.17MN/A$104.30M
    Capital expenditures$848.00K$154.00K$13.74M$30.60M$44.97M$9.82M$2.46M$11.12M$29.39M
    Free cash flow-$104.72M-$110.29M-$102.08M-$16.55M-$133.97M-$51.09M-$18.63MN/A$74.90M
    Investing cash flow$107.50M$47.48M$61.13M-$13.13M-$298.34M-$22.76M-$19.83MN/AN/A
    Financing cash flow$173.00K$74.56M-$9.72M$27.16M$417.77M$47.69M$74.84M$98.09MN/A
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$22.23M-$19.83M-$25.26M-$16.08M-$25.58M-$27.59M-$34.62M-$24.22M-$28.33M-$27.33M-$30.25M-$26.23M
    Capital expenditures$535.00K$694.00K$584.00K$139.00K$195.00K$317.00K$475.00K$154.00K$804.00K$265.00K$539.00K$980.00K
    Free cash flow-$22.76M-$20.53M-$25.85M-$16.22M-$25.78M-$27.91M-$35.10M-$24.38M-$29.14M-$27.60M-$30.79M-$27.21M
    Last 12 quarters

    Frequently Asked Questions About IPSC

    What is Century Therapeutics' annual revenue?

    Century Therapeutics reported revenue of $109.16M for the fiscal year ended Dec 31, 2025.

    How fast is Century Therapeutics' revenue growing?

    Revenue was up 1556.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 175.9%.

    Is Century Therapeutics profitable?

    No. Century Therapeutics reported net income of -$9.58M for the fiscal year ended Dec 31, 2025, with a net margin of -8.8%.

    How much free cash flow does IPSC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$103.88M minus capital expenditures of $848.00K produced free cash flow of -$104.72M.

    How much debt does Century Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $3.76M and cash and equivalents of $61.85M.